Dec 3, 2024 | Press Releases
Registration Link for Presentation and live Q&A to take place, Tuesday, December 10, 2024 at 12:00 pm ESTMarlborough, Massachusetts–(Newsfile Corp. – December 3, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology...
Nov 19, 2024 | Press Releases
–Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts–(Newsfile Corp. – November 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a...
Nov 14, 2024 | Press Releases
Marlborough, Massachusetts–(Newsfile Corp. – November 14, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing...
Nov 7, 2024 | Press Releases
Presenting new clinical data from Phio’s on-going Phase 1b trialMarlborough, Massachusetts–(Newsfile Corp. – November 7, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a...
Nov 1, 2024 | Press Releases
Registration Link for Presentation and live Q&A to take place, Thursday, November 7 at 12:00 pm ESTMarlborough Massachusetts–(Newsfile Corp. – November 1, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company...
Oct 24, 2024 | Press Releases
New clinical data from Phio’s on-going Phase 1b trial to be presentedMarlborough, Massachusetts–(Newsfile Corp. – October 24, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
